Skip to main content

Table 8 Summary statistics for the owner efficacy scores from Day 1 to VF

From: Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial

Response Visits Robenacoxib (s.c. + oral) Meloxicam s.c. + oral placebo P value (Mann–Whitney test) Quotient robenacoxib:meloxicam (RMANCOVA) P value (RMANCOVA) Transformation for RMANCOVA analysis
   Mean (SD) Mean (SD) Mean 95% CI   Exponential P value for normality (Shapiro-Wilks test)
Level of activity D1-VF 0.62 (0.53) 0.64 (0.61) 0.96 0.972 0.658–1.373 0.87 0 (log) <0.0001
Behaviour D1-VF 0.29 (0.38) 0.31 (0.34) 0.57 1.285 0.731–2.240 0.34 −1 (reciprocal) <0.0001
Appetite D1-VF 0.38 (0.48) 0.37 (0.49) 0.69 1.006 0.551–1.672 0.98 −1 (reciprocal) <0.0001
Interaction D1-VF 0.23 (0.34) 0.26 (0.33) 0.70 1.306 0.696–2.452 0.36 −1 (reciprocal) <0.0001
Global owner score D1-VF 1.52 (1.42) 1.58 (1.45) 0.87 1.050 0.719–1.482 0.78 0 (log) <0.0001
  1. CI: confidence interval; VF: final visit.
  2. Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. All assessments made by the owners are secondary end points. Assessments were made daily from the day after surgery (Day 1) to VF.
  3. Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.
  4. The level of activity, behaviour, appetite and interaction scores ranged from 0 to 3. The global owner score ranged from 0 to 12.